Nocion Therapeutics, a Cambridge, MA–based company targeting neurons mediating cough, itch, pain and inflammation without the addictive properties of opioids, raised $27M in Series A funding.
The round was led by F-Prime Capital Partners and Canaan, with participation from Partners Innovation Fund, and BioInnovation Capital.
The company intends to use the funds to finance it from discovery through clinical proof of concept in patients.
Led by Dr. Richard Batycky, CEO, Nocion Therapeutics develops novel pharmaceuticals that will provide targeted and sustained relief for the treatment of serious medical conditions including cough, itch, pain and inflammation.
These pharmaceuticals are highly selective, locally confined, and silence sensory neurons activated by noxious stimuli, without inhibiting neurons mediating movement or touch.
The approach is based on its understanding of how sensory neurons respond to noxious stimuli.
Nocion’s scientific founders are:
– Dr. Bruce Bean, who is the Robert Winthrop Professor of Neurobiology at Harvard Medical School (HMS);
– Dr. Clifford Woolf, a Professor of Neurobiology and of Neurology and Director of the F.M. Kirby Neurobiology Center and Neurobiology Program at Boston Children’s Hospital and HMS; and
– Dr. Bruce Levy, MD, Chief of the Division of Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital, Medical Director of the Brigham Lung Center, and the Parker B. Francis Professor of Medicine at HMS.
Nocion closed its seed financing in the first quarter of 2018 and is in operations at LabCentral in Cambridge, Massachusetts.